Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran : randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine.
DESIGN: Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.
SETTING: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan.
PARTICIPANTS: 20 000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1.
INTERVENTION: 5 µg vaccine or placebo with the interval of 28 days.
MAIN OUTCOME MEASURES: Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial.
RESULTS: 20 000 participants were recruited and randomly assigned to receive BIV1-CovIran (n=13 335 (66.7%)) or placebo (n=6665 (33.3%)). Participants' mean age was 38.3 (standard deviation 11.2) years, and 6913 (34.6%) were female. Among vaccinated participants that had covid-19 reported during the follow-up (median 83 days), 758 (5.9%) had symptoms, 144 (1.1%) had severe infection, and seven (0.1%) were critical. Among participants who received placebo during the follow-up, 688 (10.7%) had symptoms, 221 (3.4%) had severe infection, and 19 (0.3%) were critical. Overall efficacy was 50.2% (95% confidence interval 44.7% to 55.0%) against symptomatic covid-19, 70.5% (63.7% to 76.1%) against severe disease, and 83.1% (61.2% to 93.5%) against critical cases. Two deaths were reported in the efficacy population in the placebo group, no deaths were from the intervention group. During follow-up, 41 922 adverse events were reported: 28 782 (68.7%) were adverse reactions, of which 19 363 (67.3%) were in the intervention group. Most adverse reactions were mild or moderate in severity (grade 1 or 2) and self-limiting. No serious adverse events were related to the injections. For variant investigation, of 119 participants positive for the SARS-CoV-2 variant, 106 (89.1%) were positive for the delta variant.
CONCLUSIONS: A two dose regimen of the BIV1-CovIran vaccine conferred efficacy of 50.2% against symptomatic covid-19, 70.5% against severe disease, and 83.1% against critical disease. Vaccination was well tolerated, with no safety concerns raised.
TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20201202049567N3.
FUNDING: Shifa-Pharmed Industrial Group.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:382 |
|---|---|
| Enthalten in: |
BMJ (Clinical research ed.) - 382(2023) vom: 21. Sept., Seite e070464 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mohraz, Minoo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 25.09.2023 Date Revised 03.10.2023 published: Electronic ErratumIn: BMJ. 2023 Sep 25;382:2193. - PMID 37748804 Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmj-2023-070464 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362313512 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362313512 | ||
| 003 | DE-627 | ||
| 005 | 20231226090957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmj-2023-070464 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362313512 | ||
| 035 | |a (NLM)37734752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mohraz, Minoo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran |b randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2023 | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: BMJ. 2023 Sep 25;382:2193. - PMID 37748804 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine | ||
| 520 | |a DESIGN: Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial | ||
| 520 | |a SETTING: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan | ||
| 520 | |a PARTICIPANTS: 20 000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1 | ||
| 520 | |a INTERVENTION: 5 µg vaccine or placebo with the interval of 28 days | ||
| 520 | |a MAIN OUTCOME MEASURES: Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial | ||
| 520 | |a RESULTS: 20 000 participants were recruited and randomly assigned to receive BIV1-CovIran (n=13 335 (66.7%)) or placebo (n=6665 (33.3%)). Participants' mean age was 38.3 (standard deviation 11.2) years, and 6913 (34.6%) were female. Among vaccinated participants that had covid-19 reported during the follow-up (median 83 days), 758 (5.9%) had symptoms, 144 (1.1%) had severe infection, and seven (0.1%) were critical. Among participants who received placebo during the follow-up, 688 (10.7%) had symptoms, 221 (3.4%) had severe infection, and 19 (0.3%) were critical. Overall efficacy was 50.2% (95% confidence interval 44.7% to 55.0%) against symptomatic covid-19, 70.5% (63.7% to 76.1%) against severe disease, and 83.1% (61.2% to 93.5%) against critical cases. Two deaths were reported in the efficacy population in the placebo group, no deaths were from the intervention group. During follow-up, 41 922 adverse events were reported: 28 782 (68.7%) were adverse reactions, of which 19 363 (67.3%) were in the intervention group. Most adverse reactions were mild or moderate in severity (grade 1 or 2) and self-limiting. No serious adverse events were related to the injections. For variant investigation, of 119 participants positive for the SARS-CoV-2 variant, 106 (89.1%) were positive for the delta variant | ||
| 520 | |a CONCLUSIONS: A two dose regimen of the BIV1-CovIran vaccine conferred efficacy of 50.2% against symptomatic covid-19, 70.5% against severe disease, and 83.1% against critical disease. Vaccination was well tolerated, with no safety concerns raised | ||
| 520 | |a TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20201202049567N3 | ||
| 520 | |a FUNDING: Shifa-Pharmed Industrial Group | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 700 | 1 | |a Vahdat, Katayoun |e verfasserin |4 aut | |
| 700 | 1 | |a Ghamari, Seyyed-Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi-Kangevari, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Ghasemi, Erfan |e verfasserin |4 aut | |
| 700 | 1 | |a Ghabdian, Yasaman |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Negar |e verfasserin |4 aut | |
| 700 | 1 | |a Pouya, Maryam Amini |e verfasserin |4 aut | |
| 700 | 1 | |a Abdoli, Asghar |e verfasserin |4 aut | |
| 700 | 1 | |a Malekpour, Mohammad-Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Koohgir, Keyvan |e verfasserin |4 aut | |
| 700 | 1 | |a Saeedi Moghaddam, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Moghadami, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Khorvash, Farzin |e verfasserin |4 aut | |
| 700 | 1 | |a Khodashahi, Rozita |e verfasserin |4 aut | |
| 700 | 1 | |a Salehi, Mohammadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Hamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ (Clinical research ed.) |d 1988 |g 382(2023) vom: 21. Sept., Seite e070464 |w (DE-627)NLM012612685 |x 1756-1833 |7 nnns |
| 773 | 1 | 8 | |g volume:382 |g year:2023 |g day:21 |g month:09 |g pages:e070464 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmj-2023-070464 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 382 |j 2023 |b 21 |c 09 |h e070464 | ||